TY - JOUR
T1 - A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma
T2 - An eastern cooperative oncology group study (E1404)
AU - Greenwald, Daniel R.
AU - Li, Hailun
AU - Luger, Selina M.
AU - Go, Ronald S.
AU - King, David
AU - Patel, Taral
AU - Gascoyne, Randy D.
AU - Kolesar, Jill
AU - Kahl, Brad S.
AU - Horning, Sandra
N1 - Funding Information:
We would like to thank Dr. Ranjana Advani for her help in study implementation and review of the manuscript. This investigation was supported by Grant CA-23318, awarded by the National Cancer Institute, DHHS. This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA21115, CA23318, CA66636, CA15488, CA21076 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
PY - 2013
Y1 - 2013
N2 - Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.
AB - Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.
KW - Diffuse large B cell lymphoma
KW - MAP kinase signaling
KW - NHL
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=84879805208&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-6-46
DO - 10.1186/1756-8722-6-46
M3 - Article
C2 - 23829878
AN - SCOPUS:84879805208
SN - 1756-8722
VL - 6
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 46
ER -